Abstract
Purpose: To investigate the predictive biomarker value of estrogen receptor 1 (ESR1) expression in tumor tissue on adjuvant chemotherapy in curatively resected colorectal cancer (CRC).Methods: A total of 467 CRC patients in 2007–2010 were retrospectively evaluated. Clinical information and follow-up data were retrieved from hospital registries and patient files. What's more, we used an external independent cohort (n = 511) from GSE39582 for further validation. Overall survival was estimated by the Kaplan–Meier method, and the survival curves were compared by log-rank tests. Cox proportional hazards models were used for multivariate analyses to calculate the hazard ratios (HRs) and test independent significance. Immunohistochemistry and Western blot were applied to detect protein expression of ESR1 in CRC patients and cell lines. The stable knockdown and overexpressed cells were transduced with the lentivirus. Cell viability was measured by an MTS reagent.Results: The predictive value of ESR1 was investigated in locally advanced CRC patients. Kaplan–Meier analysis indicated that ESR1 expression was significantly correlated with OS in patients receiving adjuvant chemotherapy from these cohorts, with p = 0.015 and p < 0.001, respectively. ESR1 expression was significantly correlated with 5-flurouracil (5-FU)-based adjuvant chemotherapy in training with an HR of 1.792 (95%CI: 1.100–2.921, p = 0.019). Downregulation of ESR1 was related with enhanced chemosensitivity to 5-FU in CRC cell lines, while upregulation of ESR1 was correlated with decreased chemosensitivity.Conclusions: The present study manifest clinical validity of ESR1 expression as a predictive biomarker on 5-FU-based adjuvant chemotherapy in stage II–III CRC.
Highlights
Colorectal cancer (CRC) incidence in China has been increasing over the past decades [1,2,3]
Our study indicated that activating phosphorylation of P65 by estrogen receptor 1 (ESR1) may play a role in the 5-FU resistance, which gave a hint to investigate NF-κB signal pathways
Our study indicated the predictive value of ESR1 in stage II–III CRC, further prospective study that validates the predictive value of ESR1 according to the MMR status in CRC is demanded
Summary
Colorectal cancer (CRC) incidence in China has been increasing over the past decades [1,2,3]. 5-Flurouracil (5-FU)based adjuvant chemotherapy is the standard treatment for locally advanced CRC patients. Up to 40% of advanced CRC patients cannot benefit from adjuvant chemotherapy and will eventually relapse [6]. Great effort has been made to identify markers to predict the benefit from adjuvant chemotherapy. The treatment is mainly based on the tumor/node/metastasis (TNM) stage. It is quite crucial to identify and validate markers from surgical pathologic samples, which enables identification of patients at high and low risk of early relapse and progression, independently of the tumor stage. The biomarkers have great implication in individualized adjuvant treatment and follow-up. The primary aim of the present study was to evaluate the tumor expression of estrogen receptor 1 (ESR1) from CRC patients in this context
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
